A semaglutide implant has been tested in people, but only for four weeks in a small, low-dose study. It has not shown that one implant can replace a year's injections. The early question was simpler: can it release the medicine into the blood, and how do people tolerate it?
Semaglutide implant: what happened
As of November 20, 2026, the day this article was written, Vivani's November 12 announcement reports the first human results for its NPM-139 implant. SLIM-1 was a Phase 1 study, the early stage of testing a treatment in people. The company calls the findings “positive.”
These are top-line results: the company's initial summary before full data are published. A press release has not undergone peer review, the independent scientific review used by journals.
The registered study design, NCT07430059, assigned participants by chance to two groups. It was open-label, meaning participants and researchers knew which treatment each person received. Vivani reports ten people per group at one Australian center.
How NPM-139 is designed to release medicine
The registry describes a small titanium implant, about 23 millimeters long and 2 millimeters across, containing liquid semaglutide. It sits under the skin of the upper arm. Vivani calls its delivery system NanoPortal and describes a design intended to release medicine steadily.
Semaglutide acts like GLP-1, a gut hormone involved in appetite and blood sugar. The implant changes how that medicine enters the body. It doesn't turn semaglutide into a different molecule.
In SLIM-1, the implant was scheduled for removal after four weeks. The comparison group received weekly Wegovy injections at the starting dose of 0.25 mg. This was a low-dose comparison, not a test against a full course of weight-management treatment.
Our semaglutide injections guide explains the existing injection routine. A new delivery device needs its own evidence even when the medicine inside is familiar.
SLIM-1 trial results: a small first look
Vivani's release states: “0 of 10 NPM-139 subjects experienced adverse events reported as treatment related.” Adverse events are health problems recorded during a study; treatment-related means investigators judged them connected to treatment.
| Finding over four weeks | NPM-139 implant | Wegovy injection |
|---|---|---|
| Participants with treatment-related events | 0 of 10 | 5 of 10, all involving the stomach or bowels |
| Reported weight loss | 0.79% | 0.82% |
Both groups lost less than one percent of body weight. Those closely spaced numbers do not establish equal weight-loss effects. Ten people per group, low doses and four weeks cannot answer the long-term comparison.
The main measurements concerned side effects and how much medicine reached the blood over time. Weight was also measured, but this was not a large weight-loss trial.
For scale, STEP 1, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults for 68 weeks. It compared weekly semaglutide with placebo, a treatment without active medicine. Its findings belong to that studied injection regimen, not this implant.
What it means for current treatment
The development gives researchers a reason to study another way of delivering semaglutide. It does not establish a reason to change an existing prescription.
As of November 20, 2026, the day this article was written, Vivani's current filing says none of its drug candidates has marketing approval anywhere. NPM-139 is different from an FDA-approved semaglutide product: the implant is not FDA-approved. It is not available by prescription anywhere or an implant that a pharmacy compounds.
Existing route choices have separate evidence. The oral semaglutide guide explains the tablet, and our GLP-1 pills versus injections comparison covers their practical differences.
Tirzepatide is a different medicine. It acts on GLP-1 and GIP, two gut-hormone signals involved in blood sugar and appetite. SLIM-1 did not compare the implant with tirzepatide. Its results cannot rank those medicines or establish how to switch between them.
What the side-effect count cannot tell us
Zero treatment-related events in ten people does not mean zero risk. An unblinded study can also be affected by expectations and judgments about which symptoms treatment caused. Larger groups and longer follow-up are needed to understand uncommon problems.
As of November 20, 2026, the day this article was written, FDA's November 9 safety communication requires GLP-1 label warnings about a potential increased risk of NAION. This is a rare eye condition caused by reduced blood flow to the optic nerve; it can cause permanent vision loss.
FDA says patients with sudden painless vision loss, blind spots, color changes or other listed vision symptoms should contact their health care professional right away. SLIM-1 cannot establish whether the implant changes that potential risk.
What happens if the implant needs removing?
The registry planned removal with local anesthetic, medicine that numbs the area. Vivani reports that insertions and removals were completed without complications. That is an early observation, not a guarantee about repeated procedures or longer use.
Future trials still need to answer practical questions. How often do pain, swelling or other insertion-site problems occur? How quickly can the device be removed if side effects become difficult? What happens to drug levels afterward?
Removal would not instantly clear medicine already in the blood. Ikushima and colleagues' injection study, Advances in Therapy, 2018, found a half-life of about one week: the time it takes the level in the blood to fall by half. That provides context, not a measured recovery timetable after implant removal.
What to watch next
As of November 20, 2026, the day this article was written, Vivani describes “once or twice-yearly administration” as its development goal. Its proposed Phase 2 trial, the next stage testing doses for keeping earlier weight loss, is “anticipated to begin in 2027.” Those are company plans, not a demonstrated dosing interval or a prescription launch date.
The next useful evidence would include full results, larger and longer trials, and outcomes after removal. FDA review would still be needed before U.S. marketing. Four weeks cannot settle what happens across six or twelve months.
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded means a pharmacy prepares medicine for a prescription. The experimental implant's results do not establish outcomes for that preparation.
A licensed provider may still prescribe — that decision is between you and your doctor.
Bringing the news to a visit
The useful conversation is about how an existing treatment fits someone's health, side effects and daily routine. Our guide to switching to the Wegovy pill covers a different delivery change with its own evidence.
At Promise, a licensed provider reviews every request, and not everyone qualifies for a prescription.





